Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease

Autoři: Lauren E. Wilson aff001;  Xuemei Luo aff002;  Xiaoyan Li aff003;  Jack Mardekian aff002;  Alessandra B. Garcia Reeves aff003;  Asheley Skinner aff001
Působiště autorů: Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC, United States of America aff001;  Pfizer, Inc., New York City, NY, United States of America aff002;  Bristol Myers-Squibb Company, New York City, NY, United States of America aff003;  University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225052



Patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease (CKD) have increased risk of adverse outcomes. This study evaluated treatment with oral anticoagulants and outcomes in elderly NVAF patients with CKD.


Retrospective observational cohort study of US Medicare fee-for-service patients aged ≥66 years with comorbid CKD (advanced: Stage 4 and higher; less advanced: Stages 1–3) and a new NVAF diagnoses from 2011–2013. All-cause mortality, stroke, major bleeding, and myocardial infarction rates were estimated for 1 year post-NVAF diagnosis. Associations between CKD stage and outcomes were evaluated with multivariate-adjusted Cox regression. We assessed oral anticoagulant (OAC) receipt within 90 days post-NVAF diagnosis and associations between OAC receipt and outcomes.


There were 198,380 eligible patients (79,681 with advanced CKD). After adjustment for age, gender, and comorbidities, advanced CKD was associated with increased mortality (Stage 5 HR 1.47; 95% CI 1.42–1.52), MI (HR 1.48; 95% CI 1.33–1.64), stroke (HR 1.23; 95% CI 1.11–1.37) and major bleed (HR 1.44; 95% CI 1.36–1.53) risks. Among Medicare Part D enrollees who survived ≥90 days post-NVAF diagnosis, 65–71% received no OACs in the first 90 days. Those receiving warfarin (HR 0.73; 95% CI 0.71–0.75) or DOACs (HR 0.52; 95% CI 0.49–0.56) within the first 90 days had reduced mortality in the period 90 days to 1 year following NVAF diagnosis compared to those without.


Elderly NVAF patients with advanced CKD (Stage 4 or higher) had higher mortality risks and serious clinical outcomes than those with less advanced CKD (Stage 1–3). OAC use was low across all CKD stages, but was associated with a lower mortality risk than no OAC use in the first year post-NVAF diagnosis.

Klíčová slova:

Death rates – Hemorrhagic stroke – Chronic kidney disease – Ischemic stroke – Medicare – Myocardial infarction – Geriatric nephrology


1. O'Neal WT, Tanner RM, Efird JT, Baber U, Alonso A, Howard VJ, et al. Atrial fibrillation and incident end-stage renal disease: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. International journal of cardiology. 2015;185:219–23. doi: 10.1016/j.ijcard.2015.03.104 25797681

2. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946–53. doi: 10.1161/CIRCULATIONAHA.111.020982 21646496

3. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. American heart journal. 2000;140(6):886–90. doi: 10.1067/mhj.2000.111111 11099992

4. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine. 2012;367(7):625–35. doi: 10.1056/NEJMoa1105594 22894575

5. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. doi: 10.1378/chest.10-0134 20299623

6. Bansal N, Xie D, Sha D, Appel LJ, Deo R, Feldman HI, et al. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN. 2018.

7. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45 e4. doi: 10.1016/j.amjmed.2009.11.025 20609686

8. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Journal of the American College of Cardiology. 2014;64(23):2471–82. doi: 10.1016/j.jacc.2014.09.051 25500231

9. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. 2014;64(21):e1–e76.

10. Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311(9):919–28. doi: 10.1001/jama.2014.1334 24595776

11. Bonde AN, Lip GYH, Kamper A-L, Fosbøl EL, Staerk L, Carlson N, et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation. Stroke. 2016;47(11):2707–13. doi: 10.1161/STROKEAHA.116.014422 27758943

12. Kumar S, de Lusignan S, McGovern A, Correa A, Hriskova M, Gatenby P, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ (Clinical research ed). 2018;360:k342.

13. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. Journal of the American Society of Nephrology. 2009;20(10):2223. doi: 10.1681/ASN.2009030319 19713308

14. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest. 2016;149(4):951–9. doi: 10.1378/chest.15-1719 26378611

15. Padrini R. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. European journal of drug metabolism and pharmacokinetics. 2018.

16. Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. British journal of haematology. 2018.

17. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46. doi: 10.1161/CIRCULATIONAHA.113.005008 24895454

18. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane database of systematic reviews. 2017;11:Cd011373. doi: 10.1002/14651858.CD011373.pub2 29105079

19. Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. International journal of nephrology and renovascular disease. 2017;10:135–43. doi: 10.2147/IJNRD.S105771 28652799

20. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circulation Cardiovascular quality and outcomes. 2012;5(1):85–93. doi: 10.1161/CIRCOUTCOMES.111.962688 22235070

21. Muntner P, Gutierrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, et al. Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015;65(2):249–58.

22. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2005;46(2):225–32.

23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. doi: 10.1378/chest.09-1584 19762550

24. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama. 2001;285(22):2864–70. doi: 10.1001/jama.285.22.2864 11401607

25. Administration USFaD. Drugs@FDA. 2018.

26. Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, Lam NN, Molnar AO, Zimmerman D, et al. Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2018;71(2):191–9.

27. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2013;127(2):224–32. doi: 10.1161/CIRCULATIONAHA.112.107128 23212720

28. Fauchier L, Bisson A, Clementy N, Vourc'h P, Angoulvant D, Babuty D, et al. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. American heart journal. 2018;198:39–45. doi: 10.1016/j.ahj.2017.12.017 29653646

29. Bansal N, Fan D, Hsu Cy, Ordonez Juan D, Go Alan S. Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease. Journal of the American Heart Association.3(5):e001303. doi: 10.1161/JAHA.114.001303 25332181

30. Keskar V, McArthur E, Wald R, Harel Z, Zimmerman D, Molnar AO, et al. The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation. Kidney international. 2017;91(4):928–36. doi: 10.1016/j.kint.2016.10.017 28017326

31. Beyer-Westendorf J, Kreutz R, Posch F, Ay C. The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. International journal of cardiology. 2018;253:71–7. doi: 10.1016/j.ijcard.2017.10.110 29306476

32. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, et al. A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Chest. 2014;145(6):1370–82. doi: 10.1378/chest.13-2103 24356875

33. Wong CX, Odutayo A, Emdin CA, Kinnear NJ, Sun MT. Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis. The American journal of cardiology. 2016;117(12):1934–41. doi: 10.1016/j.amjcard.2016.03.042 27237624

34. Shin J-I, Secora A, Alexander GC, Inker LA, Coresh J, Chang AR, et al. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology. 2018;13(8):1144–52. doi: 10.2215/CJN.13811217 30002224

Článek vyšel v časopise


2019 Číslo 11